Daniel Ripley - Conatus Pharmaceuticals Insider

Conatus Pharmaceuticals Inc -- USA Stock  

USD 4.09  0.18  4.22%

Senior Vice President - Business Development, Program and Alliance Management

Mr. Daniel L. Ripley serves as Senior Vice President Business Development, Program and Alliance Management of Conatus Pharmaceuticals Inc. He has 15 years of integrated business development experience in the initiation and execution of strategic business transactions in emerging growth life science companies. He has led licensing, commercial analysis, partnering initiatives, and intellectual property enforcement to drive business development of earlytolate stage products in a wide variety of therapeutic areas and technologies. He served as Senior Director of Business Development at Apricus Biosciences from 2011 through 2012, and prior to that was a senior business development consultant to biotechnology companies in the San Diego area from 2010 through 2011, Vice President of Business Development at BioBlocks, Inc. from 2009 through 2010, Senior Director, Head of Business Development at Kalypsys, Inc. from 2006 through 2008, and Director of Business Development at Isis Pharmaceuticals from 2000 through 2006. During this timeframe, he executed multiple licensing and drug discovery collaborations with pharmaceutical and biotechnology companies that included Pfizer, Oncogenex, Alnylam, Amgen, GSK, Sanofi, and Alcon
  President Since 2017  MBA    
858-376-2600  http://www.conatuspharma.com
Ripley holds an M.B.A. with an emphasis in Finance and a B.S. in Microbiology, both from San Diego State University.

Management Efficiency

The company has return on total asset (ROA) of (22.75) % which means that it has lost $22.75 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (74.5) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 12.97 M in liabilities with Debt to Equity (D/E) ratio of 41.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals Inc has Current Ratio of 2.64 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 6 records

PRESIDENT Since

Erez FeigeVascular Biogenics Ltd
2014
Eyal BreitbartVascular Biogenics Ltd
2014
Athena KartsaklisVBI Vaccines Inc
2017
Adam BuckleyVBI Vaccines Inc
N/A
Yael CohenVascular Biogenics Ltd
2008
T BuckleyVBI Vaccines Inc
N/A

Entity Summary

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Conatus Pharmaceuticals Inc (CNAT) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 25 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Conatus Pharmaceuticals Inc to your portfolio

Top Management

Conatus Pharmaceuticals Leadership Team
Edward Smith, President, MBA
Michelle Vandertie, Executive
Dan Kisner, Director
James Scopa, Director
Steven Mento, CEO
Daniel Kisner, Director
Preston Klassen, Director
David Hale, Chairman
Harold Wart, Director, Ph.D
William LaRue, Director, MBA
Alfred Spada, Founder, Ph.D
Charles Cashion, President, MBA
Daniel Ripley, President, MBA
Keith Marshall, President, MBA
Louis Lacasse, Director, MBA
Shahzad Malik, Director
David Hagerty, President

Stock Performance

Conatus Pharmaceuticals Performance Indicators